Polycythemia Vera Onset and Management in Adults

Age Distribution and Risk Stratification

The median age at diagnosis of polycythemia vera is approximately 60 years, establishing it as predominantly an adult-onset disease, with approximately 7% of patients diagnosed before age 40 years, according to the Mayo Clinic guidelines 1, 2
Children are rarely diagnosed with polycythemia vera, making pediatric presentation exceptional rather than typical, with a slight male preponderance of 1.2:1 ratio 1, 2
Low-risk disease is defined as age younger than 60 years with no history of thrombosis, while high-risk disease includes age 60 years or older or a positive history of thrombosis, as per the Mayo Clinic guidelines 3, 4

Younger patients (<60 years) without thrombosis history may be managed with phlebotomy alone plus low-dose aspirin, according to the Mayo Clinic guidelines 3
In younger high-risk patients, interferon-α is preferred over hydroxyurea or busulfan due to concerns about long-term leukemogenicity, though evidence for this concern remains limited, as recommended by the Mayo Clinic guidelines 3, 4
Women of childbearing age should receive interferon-α rather than hydroxyurea or busulfan due to theoretical teratogenicity risk, as advised by the Mayo Clinic guidelines 3, 4
Elderly patients (>60 years) with life expectancy <10 years may be candidates for radioactive phosphorus (³²P) if compliance is an issue, according to the Mayo Clinic guidelines 3

The risk of disease transformation increases progressively beyond the first decade, as noted in the Mayo Clinic guidelines 3